Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid–Producing Microbiota in the Gut
The DOI matches its Crossref record; 38 of the 40 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Recent studies suggest the beneficial effects of metformin on glucose metabolism may be microbially mediated. We examined the association of type 2 diabetes, metformin, and gut microbiota in community-dwelling Colombian adults. On the basis of previous research, we hypothesized that metformin is associated with higher levels of short-chain fatty acid (SCFA)–producing and mucin-degrading microbiota. RESEARCH DESIGN AND METHODS: Participants were selected from a larger cohort of 459 participants. The present analyses focus on the 28 participants diagnosed with diabetes—14 taking metformin— and the 84 participants without diabetes who were matched (3-to-1) to participants with diabetes by sex, age, and BMI. We measured demographic information, anthropometry, and blood biochemical parameters and collected fecal samples from which we performed 16S rRNA gene sequencing to analyze the composition and structure of the gut microbiota. RESULTS: We found an association between diabetes and gut microbiota that was modified by metformin use. Compared with participants without diabetes, participants with diabetes taking metformin had higher relative abundance of Akkermansia muciniphila, a microbiota known for mucin degradation, and several gut microbiota known for production of SCFAs, including Butyrivibrio, Bifidobacterium bifidum, Megasphaera, and an operational taxonomic unit of Prevotella. In contrast, compared with participants without diabetes, participants with diabetes not taking metformin had higher relative abundance of Clostridiaceae 02d06 and a distinct operational taxonomic unit of Prevotella and a lower abundance of Enterococcus casseliflavus. CONCLUSIONS: Our results support the hypothesis that metformin shifts gut microbiota composition through the enrichment of mucin-degrading A. muciniphila as well as several SCFA-producing microbiota. Future studies are needed to determine if these shifts mediate metformin’s glycemic and anti-inflammatory properties.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Biguanides/metformin, the first-line therapeutics for T2D, modifies microbiota leading to an increase in A. muciniphila, as well as several SCFA-producing microbiota, favoring an improvement on mucin-producing goblet cells, pro-inflammatory IL-6, and glucose tolerance [304].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [304]
In the citing paper
“In human diabetic individuals, metformin was shown to shift gut microbiota composition to predominantly short-chain fatty-acid producing microbes”
From Benefits of Metformin in Attenuating the Hallmarks of Aging (2020) · cites this paper as de la Cuesta-Zuluaga et al. 2017
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192 · cited 2×
“pairwise tests among groups of participants using the unpaired Wilcoxon rank sum test, and finally uses LDA to estimate the effect size of each differentially abundant OTU (24).”
MethodKozich, J. J., Westcott, S. L., Baxter, N. T., Highlander, S. K., & Schloss, P. D. (2013) · Applied and Environmental Microbiology · doi:10.1128/aem.01043-13 · Cited by 7,112
A metagenome-wide association study of gut microbiota in type 2 diabetes
Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., Liang, S., Zhang, W., Guan, Y., Shen, D., et al. (2012) · Nature · doi:10.1038/nature11450 · Cited by 6,762 · cited 1×
“Given the considerable variation in the microbiota associated with type 2 diabetes and that the gut microbiota of Colombians is different to that of other populations (18), we hypothesized that the microbial taxa involved in the type 2 diabetes dysbiosis of Colombians are different to those observed in Chinese and Eur…”
BackgroundLinking long-term dietary patterns with gut microbial enterotypes
Wu, G. D., Chen, J., Hoffmann, C., Bittinger, K., Chen, Y.-Y., Keilbaugh, S. A., Bewtra, M., Knights, D., Walters, W. A., Knight, R., et al. (2011) · Science · doi:10.1126/science.1208344 · Cited by 6,513 · cited 1×
“Prevotella has been associated with carbohydrate-baseddiets anddegradation of complex polysaccharides (26), whereas E.”
BackgroundCross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity
Everard, A., Belzer, C., Geurts, L., Ouwerkerk, J. P., Druart, C., Bindels, L. B., Guiot, Y., Derrien, M., Muccioli, G. G., Delzenne, N. M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219451110 · Cited by 4,511 · cited 3×
“abundance of Akkermansia muciniphila (11–13), a mucin-degrading bacteria that has been shown to reverse metabolic disorders (1,12).”
BackgroundInfluentialGut metagenome in European women with normal, impaired and diabetic glucose control
Karlsson, F. H., Tremaroli, V., Nookaew, I., Bergström, G., Behre, C. J., Fagerberg, B., Nielsen, J., & Bäckhed, F. (2013) · Nature · doi:10.1038/nature12198 · Cited by 3,115 · cited 1×
“Given the considerable variation in the microbiota associated with type 2 diabetes and that the gut microbiota of Colombians is different to that of other populations (18), we hypothesized that the microbial taxa involved in the type 2 diabetes dysbiosis of Colombians are different to those observed in Chinese and Eur…”
BackgroundGut Microbiota in Human Adults with Type 2 Diabetes Differs from Non-Diabetic Adults
Larsen, N., Vogensen, F. K., van den Berg, F. W. J., Nielsen, D. S., Andreasen, A. S., Pedersen, B. K., Al-Soud, W. A., Sørensen, S. J., Hansen, L. H., & Jakobsen, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009085 · Cited by 2,952
Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism
Wahlström, A., Sayin, S. I., Marschall, H.-U., & Bäckhed, F. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.005 · Cited by 2,851 · cited 1×
“through effects on bile acid secretion (31).”
Cited by
Items 301–400 of 731
Petakh, P., Kamyshna, I. I., Nykyforuk, A., Yao, R., Imbery, J. F., Oksenych, V., Korda, M. M., & Kamyshnyi, O. (2022) · Viruses · doi:10.3390/v14030477 · Cited by 36
Huang, Y., Lou, X., Jiang, C., Ji, X., Tao, X., Sun, J., & Bao, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1044030 · Cited by 35
“The STAMP analysis showed that the abundance of Clostridium sensu stricto (P=0.031), Akkermansia (P=0.046) and Streptococcus (P=0.047) frontiersin.org was significantly higher in group B than that in group A after treatment.”
BackgroundInfluentialGut microbiota, immunity, and bile acid metabolism: decoding metabolic disease interactions
Zhao, Q., Wu, J., Ding, Y., Pang, Y., & Jiang, C. (2023) · Life Metabolism · doi:10.1093/lifemeta/load032 · Cited by 35
The Microbiome and Its Implications in Cancer Immunotherapy
Choudhry, H. (2021) · Molecules · doi:10.3390/molecules26010206 · Cited by 31
Impact of non-antibiotic drugs on the human intestinal microbiome
Bastard, Q. L., Berthelot, L., Soulillou, J., & Montassier, E. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1952075 · Cited by 35
“taking metformin compared to non-treated ones [57].”
BackgroundInfluentialWei, T., Cao, W., Yu, B., Chen, H., Gong, R., Luorong, Q., Luo, J., Yao, L., & Zhang, D. (2022) · Food & Function · doi:10.1039/d1fo04260b · Cited by 32
Yeh, W., Hsu, Y.-J., Ho, C.-S., Ho, H.-H., Kuo, Y., Tsai, S., Huang, C., & Lee, M. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.896503 · Cited by 32
“muciniphila, a gut microbe known for mucin degradation and SCFA production, is thought to be positively correlated with exercise performance in its abundance (57), in addition to maintaining gut barrier function and glucose homeostasis (46).”
BackgroundSee, M. S., Li, C. X., Khoo, S. C., Abidin, S. Z., Sonne, C., & Ling, N. (2025) · Journal of Hazardous Materials Advances · doi:10.1016/j.hazadv.2025.100612 · Cited by 45
Glaros, S. B., Mishra, S. P., Jain, S., Davis, F., Gabel, S. A., Mueller, G. A., Jarmusch, A. K., Mabundo, L. S., Courville, A. B., Walter, M. F., et al. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2558071 · Cited by 32
“25 Yet, numerical increases in one or two species may be less important compared to the changes in gut-related microbiome functional capacity.”
Maniar, K., Singh, V., Moideen, A., Bhattacharyya, R., Chakrabarti, A., & Banerjee, D. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.021 · Cited by 30
Srinivasan, S., Beamer, M. A., Fiedler, T. L., Austin, M. N., Sizova, M. V., Strenk, S. M., Agnew, K. J., Gowda, G. A. N., Raftery, D., Epstein, S. S., et al. (2019) · INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY · doi:10.1099/ijsem.0.004702 · Cited by 34
el-Din, S. H. S., Salem, M., El-Lakkany, N. M., Hammam, O. A., Nasr, S. M., Okasha, H., Ahmed, L. N., Saleh, S., & Botros, S. S. (2021) · Human & Experimental Toxicology · doi:10.1177/0960327121999445 · Cited by 30
“The possible mechanism by which MTF affect gut microbiota is likely due to its action on increasing the abundance of Akkermansia muciniphila,(13) which protects the mucus layer and decreases the permeability of the gut barrier, preventing the LPS from entering the blood circulation.(45) Probiotics have been appeared t…”
BackgroundHu, N., Zhang, Q., Wang, H., Yang, X., Jiang, Y., Chen, R., & Wang, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.794103 · Cited by 36
Chow, E., Yang, A., Chung, C. H. L., & Chan, J. C. N. (2022) · Pharmaceuticals · doi:10.3390/ph15040442 · Cited by 35
“Whilst Bifidobacterium species had been shown to induce gene expression involved in carbohydrate metabolism [32], Prevotella species could degrade starch [31] and metabolize fructose to produce medium-chain carboxylic acids with improved fuel transport [33].”
BackgroundResultHong, X., Yu, T., Huang, X., Wang, J., Sun, T., Yan, T., Zhou, C., Chen, H., Su, W., Du, W., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02044-6 · Cited by 31
Type 2 Diabetes and Bacteremia
Sato, J., Kanazawa, A., & Watada, H. (2017) · Annals of Nutrition and Metabolism · doi:10.1159/000479919 · Cited by 34
Luo, C., Wang, X., Huang, H., Mao, X., Zhou, H., & Liu, Z. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00371 · Cited by 31
Association of suboptimal health status with intestinal microbiota in Chinese youths
Sun, Q., Xu, X., Zhang, J., Sun, M., Tian, Q., Li, Q., Cao, W., Zhang, X., Wang, H., Liu, J., et al. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14880 · Cited by 29
Molina‐Vega, M., César, M. J. P., Gutiérrez‐Repiso, C., Fernández‐Valero, A., Lima-Rubio, F., González‐Romero, S., Moreno‐Indias, I., & Tinahones, F. J. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112465 · Cited by 34
Lin, H., Chen, S., Shen, L., Hu, T., Cai, J., Zhan, S., Liang, J., Huang, M., Xian, M., & Wang, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.773722 · Cited by 32
Wu, X., Zhao, L., Zhāng, Y., Li, K., & Yang, J. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1166685 · Cited by 31
Human gut microbiome: Therapeutic opportunities for metabolic syndrome—Hype or hope?
Horvath, A., Žukauskaitė, K., Hazia, O., Balázs, I., & Stadlbauer, V. (2023) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.436 · Cited by 33
“147,148 Another study by Sun et al, 2018 showed the decreased abundance of Bacteroides fragilis , which is a bile acid metabolizing bacterium, in the group of metformin treated diabetic patients, and a prominent increase in glycoursodeoxycholic acid levels.”
BackgroundResearch Progress of Microbiota-Gut-Brain Axis in Parkinson's Disease
Zhang, W., Ye, Y., Song, J., Sang, T., Xia, T., Xie, L., Qiu, X., Zeng, Q., & Luo, X. (2023) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2206157 · Cited by 32
“[65] re-ported that diabetic participants taking metformin had a higher relative abundance of the probiotics Butyrivibrio , Bi-fidobacterium bifidum , Megasphaera and Prevotella than non-diabetic participants.”
BackgroundStagi, S., Ricci, F., Bianconi, M., Sammarco, M., Municchi, G., Toni, S., Lenzi, L., Verrotti, A., & de Martino, M. (2017) · Nutrients · doi:10.3390/nu9050524 · Cited by 32
“Other studies in animal models disclosed an increase of Clostridium cocleatum [60], Butyrivibrio, Bifidobacterium bifidum, and Megasphaera [61].”
ResultAdherence to metformin and the onset of rheumatoid arthritis: a population-based cohort study
Naffaa, M. E., Rosenberg, V., Watad, ., Tiosano, S., Yavne, Y., Chodick, G., Amital, H., & Shalev, V. (2020) · Scandinavian Journal of Rheumatology · doi:10.1080/03009742.2019.1695928 · Cited by 31
A new aspect of an old friend: the beneficial effect of metformin on anti-tumor immunity
Kim, K., Yang, W., Jung, Y., & Cha, J. (2020) · BMB Reports · doi:10.5483/bmbrep.2020.53.10.149 · Cited by 31
Anwardeen, N. R., Naja, K., & Elrayess, M. A. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1506767 · Cited by 33
Anti-Aging Effect of Metformin: A Molecular and Therapeutical Perspective
Torres, W., Nava, M., Galbán, N., Gómez, Y., Morillo, V., Rojas, M., Cano, C., Chacín, M., D’Marco, L., Herazo-Beltrán, Y., et al. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200716161610 · Cited by 30
Ding, Q., Tian, J., Li, M., Lian, F., Zhao, L., Wei, X., Han, L., Zheng, Y., Gao, Z., Yang, H., et al. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.530160 · Cited by 30
Kostiuchenko, O., Kravchenko, N., Markus, J., Burleigh, S., Fedkiv, O., Cao, L., Letašiová, S., Skibo, G. G., Hållenius, F. F., & Prykhodko, O. (2022) · Metabolites · doi:10.3390/metabo12111027 · Cited by 28
Metformin as a booster of cancer immunotherapy
Panaampon, J., Zhou, Y., & Saengboonmee, C. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110528 · Cited by 31
Health Impact and Therapeutic Manipulation of the Gut Microbiome
Daliri, E. B., Ofosu, F. K., Chelliah, R., Lee, B. H., & Oh, D. (2020) · Microarrays · doi:10.3390/ht9030017 · Cited by 28
A comprehensive review for gut microbes: technologies, interventions, metabolites and diseases
Qi, C., Wang, P., Fu, T., Lu, M., Cai, Y., Chen, X., & Cheng, L. (2021) · Briefings in Functional Genomics · doi:10.1093/bfgp/elaa029 · Cited by 29
The Hormetic Effect of Metformin: “Less Is More”?
Panfoli, I., Puddu, A., Bertola, N., Ravera, S., & Maggi, D. C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126297 · Cited by 30
“Indeed, MTF treatment leads to a marked increase in the bacterium Akkermansia muciniphila, a mucin-degrading bacterium, which plays an important role in maintaining the integrity of the mucin layer, probably by improving the number of mucin-producing globet cells [67,95].”
BackgroundLiu, Y., Liu, C., An, D.-Y., Deng, S., & Liu, G. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107844 · Cited by 29
Wei, S., Brejnrod, A., Trivedi, U., Mortensen, M. S., Johansen, M. Y., Karstoft, K., Vaag, A. A., Ried‐Larsen, M., & Sørensen, S. J. (2021) · Gut Microbes · doi:10.1080/19490976.2021.2005407 · Cited by 31
Şahin, K., Şahintürk, Y., Köker, G., Köker, G. Ö., Bostan, F., Kök, M., Uyar, S., & Çekın, A. H. (2022) · The Turkish Journal of Gastroenterology · doi:10.5152/tjg.2022.211063 · Cited by 32
Obesity is the main driver of altered gut microbiome functions in the metabolically unhealthy
de la Cuesta‐Zuluaga, J., Huus, K. E., Youngblut, N. D., Escobar, J. S., & Ley, R. E. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2246634 · Cited by 30
Self-citationMetformin Reverses Hashimoto's Thyroiditis by Regulating Key Immune Events
Jia, X., Zhai, T., Qu, C., Ye, J., Zhao, J., Liu, X., Zhang, J., & Qian, Q. (2021) · Frontiers in Cell and Developmental Biology · doi:10.2139/ssrn.3782444 · Cited by 28
Multi-target regulation of intestinal microbiota by berberine to improve type 2 diabetes mellitus
He, Q., Dong, H., Guo, Y., Gong, M., Xia, Q., Lu, F., & Wang, D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1074348 · Cited by 27
“SCFAsproducing bacteria (Butyrivibrio, Bifidobacterium bifidum, Megasphaera, and Prevotella) decreased significantly during T2DM, so the protective effect of SCFAs decreased accordingly (27).”
BackgroundMicrobiota: A potential orchestrator of antidiabetic therapy
Liu, B., Zhang, L., Yang, H., Zheng, H., & Liao, X. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.973624 · Cited by 31
“Similar with the results observed in rodents, administration of metformin to T2D patients increased the relative abundances of Lactobacillus and Akkermansia, as well as the SCFAs-producing bacteria such as Bifidobacterium, Prevotella, Megasphaera and Butyrivibrio (60).”
ResultMethodology for biomarker discovery with reproducibility in microbiome data using machine learning
Rojas-Velázquez, D., Kidwai, S., Kraneveld, A. D., Tonda, A. P., Oberski, D. L., Garssen, J., & Lopez‐Rincon, A. (2024) · BMC Bioinformatics · doi:10.1186/s12859-024-05639-3 · Cited by 30
Gao, Y., Zhao, T., Lv, N., Liu, S., Yuan, T., Fu, Y., Zhao, W., & Zhu, B. (2024) · Endocrine · doi:10.1007/s12020-024-03828-x · Cited by 27
Larsson, A. H., Ericson, U., Jönsson, D., Miari, M., Athanasiadis, P., Baldanzi, G., Brunkwall, L., Hellstrand, S., Klinge, B., Melander, O., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-71571-4 · Cited by 27
Perazza, F., Leoni, L., Selvatici, B., Girolami, F., Bonalumi, A., Beretta, A., Ferri, S., Petroni, M. L., Piscaglia, F., Ravaioli, F., et al. (2025) · Nutrients · doi:10.3390/nu17111906 · Cited by 26
Gut Feelings: How Microbes, Diet, and Host Immunity Shape Disease
Theis, B. F., Park, J. S., Kim, J. S., Zeydabadinejad, S., Vijay–Kumar, M., Yeoh, B. S., & Saha, P. (2025) · Biomedicines · doi:10.3390/biomedicines13061357 · Cited by 25
Yan, N., Wang, L., Li, Y., Wang, T., Yang, L., Yan, R., Wang, H., & Jia, S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254321 · Cited by 30
“MET is the most frequently administered medication to treat patients with T2DM via increasing mucin-degrading Akkermansia [60].”
BackgroundResultInfluentialChen, Y., & Wang, M. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s334325 · Cited by 25
Oral Metformin Inhibits Choroidal Neovascularization by Modulating the Gut-Retina Axis
Zhang, J. Y., Xiao, J. F., Xie, B., Barba, H., Boachie-Mensah, M., Shah, R. N., Nadeem, U., Spedale, M., Dylla, N. P., Lin, H., et al. (2023) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.64.15.21 · Cited by 26
“60–62 SCFAs regulate intestinal epithelial integrity and host immunity, with studies suggesting that regulation of retina-specific T-cells may rely on gut microbiota interactions.”
BackgroundInteractions between Gut Microbiota and Oral Antihyperglycemic Drugs: A Systematic Review
Mîndrescu, N. M., Guja, C., Jinga, V., Ispas, S., Curici, A., Twakor, A. N., & Stoian, A. P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063540 · Cited by 25
Metformin exerts anti-obesity effect via gut microbiome modulation in prediabetics: A hypothesis
Maniar, K., Moideen, A., Bhattacharyya, R., & Banerjee, D. (2017) · Medical Hypotheses · doi:10.1016/j.mehy.2017.06.001 · Cited by 26
“In a Colombian study comparing the differences in the composition of gut microbiome between obese individuals with and without diabetes, it was found that metformin users had a distinct microbiota compared to diabetic individuals not taking metformin and non-diabetic obese individuals [43].”
BackgroundMandal, R. K., Crane, R. J., Berkley, J. A., Gumbi, W., Wambua, J., Ngoi, J. M., Ndungu, F. M., & Schmidt, N. W. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy740 · Cited by 26
Lai, X., Liu, B., Wan, Y., Zhou, P., Li, W., Hu, W., & Gong, W. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113683 · Cited by 25
Microbes and medicines: interrelationships between pharmaceuticals and the gut microbiome
Al-Btoosh, S., Donnelly, R. F., & KELLY, S. C. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2604867 · Cited by 27
The Emerging Role of Microbiota and Microbiome in Pancreatic Ductal Adenocarcinoma
Čierniková, S., Novisedláková, M., Cholujová, D., Števurková, V., & Mego, M. (2020) · Biomedicines · doi:10.3390/biomedicines8120565 · Cited by 24
Yan, C., Zhang, C., Cao, X., Feng, B., & Li, X. (2020) · Molecules · doi:10.3390/molecules25245857 · Cited by 24
Obesity-Associated Non-T2 Mechanisms in Obese Asthmatic Individuals
Shailesh, H., Bhat, A. A., & Janahi, I. A. (2023) · Biomedicines · doi:10.3390/biomedicines11102797 · Cited by 26
Ropot, A. V., Karamzin, A. M., & Sergeyev, O. V. (2020) · Current Microbiology · doi:10.1007/s00284-020-01992-7 · Cited by 26
“4 times higher in people with T2D treated with metformin compared with that in participants with T2D who did not receive it [54].”
ResultHou, K., Zhang, S., Wu, Z., Zhu, D., Chen, F., Lei, Z.-N., Liu, W., Xiao, C., & Chen, Z.-S. (2022) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2021.6323 · Cited by 33
“in the gut of T2D patients, which benefits them in maintaining glucose metabolism homeostasis [38].”
BackgroundMetformin: Targeting the Metabolo-Epigenetic Link in Cancer Biology
Cuyàs, E., Verdura, S., Martín-Castillo, B., & Menéndez, J. A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.620641 · Cited by 28
“In diabetic individuals, metformin can also shift gut microbiota composition through the enrichment of predominantly SCFA-producing bacteria (74, 75).”
BackgroundZhang, Y., Wang, C., Su, W., Jiang, Z., He, H., Gong, T., Kai, L., Xu, H., Wang, Y., & Lu, Z. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1003498 · Cited by 25
Liu, J., Zhang, M., Deng, D., & Zhu, X. M. (2023) · Archives of Pharmacal Research · doi:10.1007/s12272-023-01445-2 · Cited by 25
de Hase, E. M., Neyrinck, A. M., Rodriguez, J., Cnop, M., Paquot, N., Thissen, J., Xu, Y., Beloqui, A., Bindels, L. B., Delzenne, N. M., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-06032-0 · Cited by 25
“For instance, metformin has been shown to modulate gut microbiota in favour of specific bacteria such as Subdoligranulum and A. mucin-iphila [5, 13, 27, 28].”
Sun, L., Jiang, J., Zeng, Y., Zhu, J., Wang, S., Huang, D., & Cao, C. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c06030 · Cited by 24
Gut Microbiota Play an Essential Role in the Antidiabetic Effects of Rhein
Wang, R., Zang, P., Chen, J.-X., Wu, F., Zheng, Z., Ma, J., Yang, C., & Du, H. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/6093282 · Cited by 26
“We used linear discriminant analysis (LDA) effect size (LEfSe) to agnostically identify microbial biomarkers [7].”
MethodMetformin can Inhibit Helicobacter Pylori Growth
Courtois, S., Bénéjat, L., Izotte, J., Mégraud, F., Varon, C., Lehours, P., & Bessède, E. (2018) · Future Microbiology · doi:10.2217/fmb-2018-0184 · Cited by 26
The role of gut microbiota dysbiosis in the inflammatory pathogenesis of diabetic retinopathy
Xie, L., & Lin, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1604315 · Cited by 28
Association of diabetes and microbiota: An update
Al-Jameel, S. S. (2021) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.04.041 · Cited by 25
Sun, X. L., Chi, X., Zhao, Y., Liu, S., & Xing, H. (2022) · Journal of Diabetes Research · doi:10.1155/2022/1826181 · Cited by 22
Systematic review of the impact of genistein on diabetes-related outcomes
Jain, R., Bolch, C., Al‐Nakkash, L., & Sweazea, K. L. (2022) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00236.2021 · Cited by 23
Li, R., Shokri, F., Lopez‐Rincon, A., Rivadeneira, F., Medina‐Gómez, C., & Ahmadizar, F. (2023) · Genes · doi:10.3390/genes14081572 · Cited by 24
Gut microbiome: New perspectives for type 2 diabetes prevention and treatment
Li, S.-X., & Guo, Y. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i31.7508 · Cited by 23
Gut microbiota differs a decade after bariatric surgery relative to a nonsurgical comparison group
Mabey, J. G., Chaston, J. M., Castro, D. G., Adams, T. D., Hunt, S. C., & Davidson, L. E. (2020) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2020.04.006 · Cited by 22
“muciniphila abundance can increase with metformin use (37,38) and may partially mediate its action (39).”
BackgroundPastor‐Villaescusa, B., Plaza‐Díaz, J., Egea-Zorrilla, A., Leis, R., Bueno, G., Hoyos, R., Vázquez‐Cobela, R., Latorre-Millán, M., Cañete, M. D., Caballero‐Villarraso, J., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111117 · Cited by 25
Al‐Muhanna, F., Dowdell, A. K., Elq, A. H. A., Albaker, W. I., Brooks, A., Al‐Sultan, A. I., Al‐Rubaish, A. M., Alkharsah, K. R., Sulaiman, R. M., Al-Quorain, A. A., et al. (2022) · BMC Microbiology · doi:10.1186/s12866-022-02714-8 · Cited by 23
Impact of grape polyphenols on Akkermansia muciniphila and the gut barrier
Mezhibovsky, E., Wu, Y., Bawagan, F. G., Tveter, K. M., Szeto, S., & Roopchand, D. E. (2022) · AIMS Microbiology · doi:10.3934/microbiol.2022035 · Cited by 22
Chang, X., Shen, Y., Yang, M., Yun, L., Liu, Z., Feng, S., Yang, G., Meng, X., & Su, X. (2024) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2024.134444 · Cited by 21
Ma, K., Chen, J., Kuang, L., Bi, J., Cheng, J., Li, F., Sun, X., Nie, X., Liu, Y., Luo, R., et al. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/1304397 · Cited by 22
The Gut Microbiota: A Clinically Impactful Factor in Patient Health and Disease
Rodriguez, D. A., Peña-Vélez, R., Monjaráz, E. M. T., Mayans, J. R., & Ryan, P. M. (2018) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-018-0036-1 · Cited by 24
Choi, B. S.-Y., Daoust, L., Pilon, G., Marette, A., & Tremblay, A. (2020) · International Journal of Obesity · doi:10.1038/s41366-020-0618-3 · Cited by 21
“Increased Akkermansia muciniphila abundance was also detected in diabetic patients taking metformin [21].”
BackgroundThe Brain-gut Axis-where are we now and how can we Modulate these Connections?
Dąbrowski, W., Siwicka-Gieroba, D., Kotfis, K., Zaid, S., Terpiłowska, S., Robba, C., & Siwicki, A. K. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666201119155535 · Cited by 24
“In addition, recent data demonstrated connection between the administration of metformin and the abundance of Akkermansia muciniphila and potentially related metabolic effects [100-103].”
BackgroundHuang, Q., Yao, F., Zhou, C., Huang, X., Wang, Q., Long, H., & Wu, Q. (2020) · World Journal of Clinical Cases · doi:10.12998/wjcc.v8.i24.6213 · Cited by 21
Gut microbiota in patients with newly diagnosed acromegaly: a pilot cross-sectional study
Hacıoğlu, A., Gündoğdu, A., Nalbantoglu, U., Karaca, Z., Urhan, M. E., Şahin, S., Dökmetaş, H. S., Kadıoğlu, P., Keleştimur, F., & Pituitary Microbiom Study Group (PITMIT-SG) (2021) · Pituitary · doi:10.1007/s11102-021-01137-4 · Cited by 21
Mohr, A. E., Jasbi, P., Wyst, K. B. V., van Woerden, I., Shi, X., Gu, H., Whisner, C. M., & Bruening, M. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-18515-y · Cited by 26
The human gut microbiome – a new and exciting avenue in cardiovascular drug discovery
Du, Y., Li, X., Su, C., Wang, L., Jiang, J., & Hong, B. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1638909 · Cited by 21
“muciniphila as well as several SCFAs-producing bacteria [75].”
BackgroundZhang, S., Zhao, X., He, X., Shi, W., & Ma, N. (2026) · Journal of Animal Science and Biotechnology/Journal of animal science and biotechnology · doi:10.1186/s40104-025-01319-1 · Cited by 24
Seicaru, E. M., Ilie, I. R. P., Cătinean, A., Craciun, A. M., & Ghervan, C. (2022) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-4248 · Cited by 23
Citrus Honey Ameliorates Liver Disease and Restores Gut Microbiota in Alcohol–Feeding Mice
Yi, S., Zhang, G., Liu, M., Yu, W., Cheng, G., Luo, L., & Ning, F. (2023) · Nutrients · doi:10.3390/nu15051078 · Cited by 20
“Costridiaceae in the FG group may be associated with diabetes mellitus [43].”
BackgroundGut microbiome in diabetic retinopathy: A systematic review and meta-analysis
Zhao, S., Qi, Y., Xu, W., & Zhang, J.-M. (2024) · Microbial Pathogenesis · doi:10.1016/j.micpath.2024.106590 · Cited by 21
Plowman, T. J., Christensen, H., Aiges, M., Fernandez, E., Shah, M. H., & Ramana, K. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105190 · Cited by 23
Host–diet–microbiota interplay in intestinal nutrition and health
Ignatiou, A., & Pitsouli, C. (2024) · FEBS Letters · doi:10.1002/1873-3468.14966 · Cited by 23
“For example, the antidiabetic drug metformin elevates the numbers of Ak. muciniphila in diet-induced obese mice [281] and individuals with T2D [282], possibly because it induces increased numbers of mucin-producing Goblet cells [281], hence indicating a microbiota-dependent mechanism for its…”
Fang, X., Wu, H., Wang, X., Lian, F., Li, M., Miao, R., Wei, J., & Tian, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.870407 · Cited by 25
“…diabetic patients on metformin had a higher relative abundance of Akkermansia muciniphila, a few gut microbiota associated with SCFAs production (including Butyrivibrio, Bifidobacterium bifidum, Megasphaera), and an operational taxonomic unit of Prevotella (de la Cuesta-Zuluaga et al., 2017).”
BackgroundKårhus, M. L., Brønden, A., Sonne, D. P., Vilsbøll, T., & Knop, F. K. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12946 · Cited by 21
Rehman, A., Satyam, S. M., El‐Tanani, M., Prabhakar, S., KUMARI, R. R., Shetty, P., Mohammed, S. S. N., Nafees, Z., & Alomar, B. (2025) · Cancers · doi:10.3390/cancers17152466 · Cited by 22
Hiratsuka, D., Matsuo, M., & Hirota, Y. (2026) · Fertility and Sterility · doi:10.1016/j.fertnstert.2026.01.010 · Cited by 20
Meier, K., Nordestgaard, A. T., Eid, A., Kongkaewpaisan, N., Lee, J. M., Kongwibulwut, M., Han, K. R., Kokoroskos, N., Mendoza, A. E., Saillant, N. N., et al. (2019) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000002249 · Cited by 19
Ericsson, A. C., Johnson, P. J., Gieche, L. M., Zobrist, C. N., Bucy, K., Townsend, K. S., Martin, L. M., & LaCarrubba, A. M. (2021) · Animals · doi:10.3390/ani11040976 · Cited by 19
Gut microbiome differences among Mexican Americans with and without type 2 diabetes mellitus
Kitten, A., Ryan, L., Lee, G. C., Flores, B. E., & Reveles, K. R. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251245 · Cited by 22
“Multiple factors can contribute to gut microbiome diversity, including diet and medications [23].”
BackgroundTorres‐Carrillo, N., Martínez‐López, E., Torres-Carrillo, N. M., López-Quintero, A., Moreno-Ortíz, J. M., González‐Mercado, A., & Gutiérrez-Hurtado, I. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242317100 · Cited by 19
Luo, C., Wang, X., Huang, H., Mao, X., Zhou, H., & Liu, Z. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05677-8 · Cited by 19
Metadata
- Authors
- de la Cuesta-Zuluaga, J., Mueller, N. T., Corrales-Agudelo, V., Velásquez-Mejía, E. P., Carmona, J. A., Abad, J. M., & Escobar, J. S.
- Affiliations
- Vidarium—Nutrition, Health and Wellness Research Center, Grupo Empresarial Nutresa, Medellin, Colombia
- Johns Hopkins University (US)
- Vidarium - Centro de Investigación en Nutrición Salud y Bienestar (CO)
- Dinámica I.P.S.—Especialista en Ayudas Diagnósticas, Medellin, Colombia
- EPS y Medicina Prepagada Suramericana S.A., Medellin, Colombia
- Corresponding author
- Escobar, Juan S.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-11-14
- Volume
- 40
- Issue
- 1
- Pages
- 54-62
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2553515186
- Cited by
- 704
- References
- 40
- Citations by year
- 2026: 55 · 2025: 69 · 2024: 86 · 2023: 80 · 2022: 106 · 2021: 78 · 2020: 87 · 2019: 62 · 2018: 45 · 2017: 33 · 2016: 1
- FWCI
- 24.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- metformin, Akkermansia muciniphila, gut microbiota, short-chain fatty acids, type 2 diabetes, mucin degradation, Butyrivibrio, Bifidobacterium bifidum, Megasphaera, Prevotella, Clostridiaceae, Enterococcus casseliflavus, fecal microbiota composition, glycemic control
- MeSH terms
- Gastrointestinal Microbiome, Adolescent, Adult, Colombia, Diabetes Mellitus, Type 2, Fatty Acids, Volatile, Feces, Female, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Mucins, RNA, Ribosomal, 16S, Case-Control Studies, Verrucomicrobia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.